A New Horizon for Heart Health: SMT's Supraflex Cruz Stent Approved in Canada

There's exciting news from the world of cardiovascular medicine, particularly for Canadians battling heart disease. Sahajanand Medical Technologies (SMT), a leading global manufacturer of medical devices based in Mumbai, India, has just announced a significant milestone: their Supraflex Cruz sirolimus-eluting coronary stent system has received a coveted Class IV medical device license from Health Canada's Medical Devices Directorate. This isn't just a regulatory formality; it's a genuine step forward, opening up a powerful new treatment option for thousands of patients across Canada.

Now, you might be wondering, what exactly does this mean? Well, simply put, the Supraflex Cruz stent is designed to treat coronary artery disease – a condition where the heart's arteries narrow, often leading to heart attacks or other serious complications. The "sirolimus-eluting" part is key here; it means the stent slowly releases a drug that helps prevent the artery from re-narrowing after the procedure. Gaining a Class IV license from Health Canada is a big deal, signifying that the device has undergone incredibly rigorous scrutiny and met the highest safety and efficacy standards required for medical devices used in life-sustaining applications.

This approval really underscores SMT's unwavering commitment to innovation and improving patient outcomes worldwide. Anil Suri, the Chief Commercial Officer at SMT, expressed this sentiment perfectly. "Receiving Health Canada approval for Supraflex Cruz is a monumental achievement for SMT," he stated. "It’s not just about market access; it's about extending our mission to provide high-quality, accessible cardiac care to even more patients. We are genuinely thrilled to bring this clinically-proven technology to Canada, a country with a significant need for advanced treatments in cardiology."

And when we talk about "clinically-proven," we're talking about robust evidence. The Supraflex Cruz stent has an impressive track record, backed by large-scale, international clinical trials. For instance, the TUXEDO-2 trial, which involved 1,800 patients suffering from diabetes and multivessel coronary artery disease, showcased the Supraflex Cruz's non-inferiority compared to other leading drug-eluting stents in terms of target lesion failure at one year. These findings were quite impactful when presented at TCT 2025.

But the evidence doesn't stop there. Another pivotal study, MULTIVESSEL TALENT, randomized 1,550 patients across 54 sites in Europe and the United Kingdom, all grappling with three-vessel coronary artery disease. Again, Supraflex Cruz demonstrated non-inferiority against a contemporary drug-eluting stent for its primary composite endpoint at 12 months. This consistent performance across diverse patient populations and complex disease presentations really speaks volumes about the stent's reliability and effectiveness. It builds on the success of the broader Supraflex family, known for its safety and efficacy.

Why is this particularly good news for Canadians? Consider these figures: In 2023, a concerning 6.3% of Canadians aged 18 and older reported a diagnosis of heart disease or a heart attack. Heart disease, tragically, was responsible for 57,890 deaths in Canada that year, making it the country's second-leading cause of death. And between April 2023 and March 2024, approximately 8.2% of Canadians over 20 were living with diagnosed ischemic heart disease, with over 170,000 new cases cropping up annually. These aren't just numbers; they represent countless lives and families affected.

With such pressing health challenges, introducing a new, proven treatment option like Supraflex Cruz is incredibly timely. SMT, already exporting to over 75 countries by March 2025, brings its extensive global experience and commitment to quality to the Canadian healthcare landscape. This approval is more than just an entry into a new market; it's a testament to SMT's dedication to combating heart disease on a global scale, now extending its reach to help Canadians live healthier, longer lives.